Participants: A total of 5005 patients with HF. Outcome measures: In-hospital and 1-year outcome. Results: The prevalence of prior stroke in patients with HF was 8.1%. Patients with stroke with HF were more likely to be admitted under the care of internists rather than cardiologists. When compared with patients without stroke, patients with stroke were more likely to be older and to have diabetes mellitus, hypertension, atrial fibrillation, hyperlipidaemia, chronic kidney disease, ischaemic heart disease, peripheral arterial disease and left ventricular dysfunction (p=0.001 for all). Patients with stroke were less likely to be smokers (0.003). There were no significant differences in terms of precipitating risk factors for HF hospitalisation between the two groups. Patients with stroke with HF had a longer hospital stay (mean±SD days; 11±14 vs 9 ±13, p=0.03), higher risk of recurrent strokes and 1-year mortality rates (32.7% vs 23.2%, p=0.001). Multivariate logistic regression analysis showed that stroke is an independent predictor of in-hospital and 1-year mortality.
INTRODUCTION
The prevalence and incidence of stroke in patients with heart failure (HF) and the temporal relation of these two diseases in terms of increasing morbidity and mortality have scarcely been reported from around the world and never from the Middle East. HF is one of the leading causes of hospitalisation, and is a significant factor for morbidity and mortality worldwide. Moreover, HF is a major risk factor for the development of ischaemic stroke with a 2-3-fold increased risk of stroke when compared with patients without HF. 1 Factors that
Strengths and limitations of this study
▪ This is the first multicentre multinational study in the Middle East to provide a report on the prevalence, demographics, management and 1-year outcome of patients hospitalised with HF in relation to a history of stroke that included a relatively large number of patients. ▪ As an observational study, the possibility for unmeasured confounding biases exists. The current study has not recorded the cognitive status and the disability status in patients with stroke, which have a major impact on morbidity. ▪ Furthermore, no information is available regarding the cause of stroke (embolic vs thrombotic), and future studies need to overcome these limitations. ▪ Mortality rates at follow-up were only recorded at 1 year without the specification of the exact date of death of each patient.
may contribute to the occurrence of stroke in HF include: atrial fibrillation (AF) or left ventricular (LV) dysfunction that are potential source embolisation. 2 3 The hypercoagulable state and reduced fibrinolysis are a consequence of the activation of the sympathetic nervous system and the reninangiotensin-aldosterone system. 4 5 In addition to endothelial dysfunction in HF, 6 7 hypotension may also be an additional risk factor for stroke as a result of HF. 8 Moreover, underlying risk factors for the development of HF, such as hypertension and diabetes mellitus, 9 can also predispose to large-artery atherosclerosis and small-vessel thrombosis and hence stroke. 10 The prevalence and incidence of prior and acute stroke in patients with HF is unclear because of the heterogeneous nature of the limited published studies, most of which were subset analyses of randomised trials rather than epidemiological studies. [11] [12] [13] [14] [15] [16] [17] Furthermore, most of the available data are mainly limited to studies conducted in the western world and data about the prevalence of prior stroke among patients hospitalised with HF are lacking. The aim of this study is to define the prevalence, clinical characteristics, precipitating factors, management and outcome of patients with stroke hospitalised with HF, using data from Gulf CARE (Gulf aCute heArt failuRe rEgistry). 18 It is hypothesised that patients with prior stroke when hospitalised with HF have worse outcomes when compared with patients with HF and without prior stroke.
PATIENTS AND METHODS

Registry design
Gulf CARE is a prospective multinational multicentre registry that recruited patients from February 2012 to November 2012 who were admitted with the final diagnosis of acute HF (AHF) in 47 hospitals in seven Middle Eastern Arab countries in the Gulf. 18 Data were collected on episodes of hospitalisation beginning with point of initial care, with patient's discharge, transfer out of hospital or in-hospital death, and for those discharged alive 3 and 12 months follow-up was obtained. Patients' recruitment was preceded by a pilot phase of 1 month in November 2011. Institutional or national ethical committee or review board approval was obtained in each of the seven participating countries, and all patients provided informed consent. Each patient was given a unique identification number to prevent double counting. The study is registered at clinicaltrials.gov with the number NCT01467973.
Patients included in this registry were men and women aged 18 years and over with AHF who were admitted to participating hospitals. AHF was defined based on the European Society of Cardiology (ESC) definition 2 and was further classified as either acute decompensated chronic HF (ADCHF) or new-onset AHF (de novo AHF) based on the ESC guidelines. ADCHF was defined as worsening of HF in patients with a previous diagnosis or hospitalisation for HF. New-onset AHF (de novo AHF) was defined as AHF in patients with no history of HF.
Patients were excluded from Gulf CARE if: (1) they were discharged from the emergency room without admission. (2) They were transferred from a non-registry hospital. (3) There was a failure to obtain informed consent. (4) Their final diagnosis was not HF, in which case they were also excluded from the final analyses. Registry organisation and Data Collection and Validation are mentioned in Gulf CARE. 18 Definitions of data variables in the chronic renal failure (CRF) are based on the ESC guidelines 2008 and the American College of Cardiology clinical data standards 2005. 19 20 Cardiomyopathy was defined as a myocardial disorder in which the heart muscle is structurally and functionally abnormal (in the absence of coronary artery disease, hypertension, valvular disease or congenital heart disease) sufficient to cause the observed myocardial abnormality. 20 Diastolic HF was defined as the presence of symptoms and/or signs of HF and a preserved LV ejection fraction (LVEF) >40%. 19 Stroke/transient ischaemic attack (TIA) was defined as a history of cerebrovascular disease, documented by any one of the following: (1) cerebrovascular ischaemic or haemorrhagic stroke: patient has a history of stroke (ie, any focal neurological deficit of abrupt onset caused by a disturbance in blood supply that did not resolve within 24 h) confirmed by a standard neurological examination with or without a positive imaging study, or an event of presumed ischaemic origin that did not resolve within 24 h, but the imaging showed a new lesion. (2) 21 
RESULTS
Patient demographics
Approximately 8.1% of Gulf CARE patients (total 5005 patients) had a history of stroke, with no significant gender or racial differences between stroke and nonstroke groups (tables 1-3). Patients with stroke with HF were older (66.5 vs 59 years, p=0.001) and more likely to have diabetes mellitus, hypertension, AF, coronary artery disease and LV dysfunction ( p=0.001). Patients with stroke were also more likely to have chronic kidney disease and to be on renal replacement therapy than patients without stroke ( p=0.001) and to have thyroid disease (6.2% vs 3.4%, p=0.001) and previous coronary artery bypass grafting (7% vs 10.9%, p=0.004) and less likely to be smokers ( p=0.003) or have a history of asthma/chronic obstructive pulmonary disease. Patients with stroke were more likely to present with ADCHF with more frequent recent (≤6 months) HF hospitalisations ( p=0.001), and more likely to be admitted under the care of internists rather than cardiologists when compared with patients without stroke.
Investigations during hospitalisation
Patients with stroke were more likely to be admitted with AF when compared with patients without stroke; atrial fibrillation/flutter (12.7% vs 24.9%, p=0.001; table 4). Patients with stroke were also more likely to have concentric LV hypertrophy (26.8% vs 32.7%, p=0.02), and less likely to have mitral regurgitation (30.4% vs 22.5%, p=0.001) with no differences in the mean EF on echocardiographic assessment between the two groups.
Patients with stroke were more likely to have a lower GFR (mean±SD; 58±36.6 vs 69±35.7, p=0.001 and, as a result, higher serum creatinine (mean±SD; 146±111 vs129±117 mg/dL, p=0.003) and blood urea (mean±SD: 12.8±9 vs 11±8.4 mg/dL, p=0.002). Patients with stroke were also more likely to have lower admission haemoglobin levels (mean±SD; 11.9±2.3 vs 12.7±2.4 mg/dL, p=0.001).
Precipitating factors, hospitalisation course and outcomes There were no significant differences in terms of precipitating factors for HF hospitalisation between the two groups (tables 5 and 6).
Patients with stroke were more likely to require invasive and non-invasive ventilations (12.4% vs 8.1%, p=0.003), (15.3% vs 8.9%, p=0.001), respectively, and were also more likely to require inotropic support (21.8% vs 15.1%, p=0.001), AF therapy (11.4% vs 5.8%, p=0.001%), renal replacement therapy (2.5% vs 4.5%, p=0.02) and blood transfusions (9.2% vs 4.7%, p=0.001) when compared with patients without stroke. Patients with stroke were also more likely to suffer recurrent strokes and have systemic infections that require antibiotic treatment (34.9% vs 23.2%, p=0.001) during the same hospitalisation when compared with patients without stroke (table 5). The clinical workup of patients with stroke showed that they were more likely to have ischaemic heart disease (59.2% vs 42.7%, p=0.01) and less likely to have other types of cardiomyopathies (13.1% vs 18.7% p=0.005), including idiopathic cardiomyopathy (9.2% vs 13.1%, p=0.02; table 5). Patients with stroke were more likely to be discharged on oral nitrates, hydralazine, statin, ACE inhibitors (ACEIs), aldosterone antagonists ( p=0.001), oral anticoagulants ( p=0.02) and clopidogrel ( p=0.01) when compared with patients without stroke (table 3). In comparison with stroke patients non-stroke patients had percutaneous coronary intervention during hospitalisation ( p=0.02).
Patients with stroke had a longer hospital stay (mean ±SD days; 11±14 vs 9±13, p=0.03) as well as a higher but statistically non-significant in-hospital (8.4% vs 6.1%, p=0.06) and a significantly higher 1-year mortality rate (32.7% vs 23.2%, p=0.001; table 5). On multivariate logistic regression analysis, stroke was an independent mortality predictor for in-hospital and 1-year follow-up (table 6) . Age, hypertension, peripheral vascular disease and AF were independent risk factors for stroke in patients with HF (table 6) .
Cardiologist vs internist care
Subanalysis of patients with prior stroke according to whether the primary care provider is a cardiologist versus internist showed the following: patients admitted to cardiologists were more likely to be prescribed clopidogrel (48.2% vs 30.3%, p=0.001) and ACEI (51.8 vs 38.1%, p=0.007) and with less incidence of recurrent stroke (2% vs11%, p=0.001), less major bleeding (0% vs 1.9%, p=0.03) and the need for blood transfusion (6.4% vs 13.5%, p=0.02) when compared with patients with prior stroke hospitalised under the care of internists. Patients with prior stroke with systemic infection requiring antibiotics were more likely to be admitted under internal medicine care (46.5% vs 27.7%, p=0.001) with higher in-hospital mortality (13.5% vs 5.2%, p=0.009) with no significant differences in the duration of hospital stay (11±17 vs 10±10 (days), p=0.33) when compared with those admitted under cardiologist care. One year follow-up showed non-significant marginally higher rehospitalisation for patients under internist care (19.3% vs 24.5%, p=0.07) with significantly higher mortality when compared with patients under cardiologist care (69.9% vs 63.2%, p=0.002; table 7).
DISCUSSION
The current registry of patients hospitalised for HF demonstrates the following: (1) stroke history is relatively common among Middle Eastern patients. (2) Patients with stroke had a higher risk of recurrent in-hospital HF is a common disease and is a major risk factor for ischaemic stroke. Stroke-related morbidity and mortality are considerably higher in patients with HF compared with patients with stroke without HF. 22 Data on the prevalence and outcome of stroke in patients hospitalised for HF are very sparse and mainly conducted in the western world. To the best of our knowledge, this is the first study from the Middle East and the developing world that explores this issue. We had previously reported a low prevalence of prior stroke in patients hospitalised with acute coronary syndrome (ACS) in the Middle East. 23 24 On the other hand, this study reports a relatively higher prevalence of stroke in patients hospitalised with HF in seven Middle Eastern countries, suggesting that prior stroke is more prevalent among patients hospitalised with HF rather than ACS in this region.
Prevalence of stroke in patients with HF
The reported prevalence of stroke in patients with HF is variable because of the heterogeneous and limited number of published studies (table 8) . [25] [26] [27] [28] [29] [30] [31] The initial risk of ischaemic stroke during the first year after diagnosis of HF was reported to be 1.8%; this compares with subsequent risk of nearly 5% at 5 years post-diagnosis. 25 Data from the Framingham Study 11 and a recent cohort study 12 indicated that the risk of ischaemic stroke is 2-3 times higher for patients with HF than it is for those without HF. According to epidemiological data, cohort studies and case series, ≈10% to 24% of all patients with stroke have HF, whereas HF is thought to be the likely cause of stroke in ≈9% of all patients. [13] [14] [15] [16] [17] A meta-analysis including 15 clinical studies and 11 cohort studies published before 2006 25 reported a stroke rate of 1.8% and 4.7% within 1 and 5 years, respectively. A recent report from the population-based, prospective Rotterdam Scan Study revealed that stroke risk is highest within 1 month after the diagnosis of HF that normalised within 6 months. 32 This study complements previous reports by showing high prevalence of prior stroke among patients hospitalised with HF in the Middle East. Moreover, patients with a prior stroke had a higher risk of recurrent strokes during the index hospitalisation. This high prevalence may be due to associated risk factors for stroke such as severe LV systolic dysfunction (44.6% had EF <35%) and AF (25%), even though there was a relatively high prevalence of associated risk factors, including LV dysfunction and AF, while the use of anticoagulants and antiplatelet agents was low In this study, we reported the use of anticoagulants (20-22%) and antiplatelets (29-41%) during hospitalisation at discharge, respectively, in patients with prior stroke; this rate may be much lower than has been reported in a EUROASPIRE III survey where antiplatelet drugs or oral anticoagulants were used by 87.2%, of patients with stroke. 33 This lower use of anticoagulants and antiplatelets in this study may have contributed to their increased risk of recurrent strokes and higher mortality rates.
Risk factors for stroke in patients with HF and outcome Present facts concerning other risk factors for stroke in HF (apart from AF as the major factor) are primarily grounded on retrospective studies, cohort studies or post-hoc analyses of large clinical trials with significant inconsistencies. 34 This study reported age, diabetes mellitus, hypertension, hyperlipidaemia, peripheral vascular disease and AF to be independently associated with recurrent stroke risk in patients with HF. The Olmsted County cohort demonstrated that prior stroke, advanced age and diabetes were relevant stroke risk factors in 630 patients with HF, 12 whereas a history of AF or hypertension did not reach statistical significance according to multivariable analysis. On the other side, a retrospective analysis of the prospective Survival and Ventricular Enlargement (SAVE) study also reported no significant impact of hypertension (and diabetes) in 2231 patients with HF. 35 In contrast to these reports, the SCD-HeFTstudy revealed an HR of 1.9 (95% CI 1.1 to 3.1) for stroke when hypertension was present at randomisation of 2144 patients with HF without AF. 9 In addition, a medical history of hypertension was associated with an increased risk of hospitalisation for stroke (HR 1.4; 95% CI 1.01 to 1.8) in 7788 patients with HF of the Digitalis Investigation Group trial. 36 Furthermore, our result is compatible from the age point of view with the Olmsted County data that revealed a significant but modest association between stroke risk and advanced age (relative risk 1.04; 95% CI 1.02 to 1.06). 12 An exploratory analysis of the SAVE study also showed similar results (relative risk of stroke 1.18; 95% CI 1.05 to 1.3, for each increase of 5 years in age), 9 while these results contradict the result of the Framingham Study that indicated that advanced age does not account for the increased risk of stroke in patients with HF 3 37 This study has shown that patients with HF with stroke had higher in-hospital mortality with longer hospital stay and that they are less likely to stay alive at 1-year follow-up, probably explained by the multiple comorbidities in this patient population. Many retrospective database analyses have shown that stroke increases the disability and mortality of patients with HF through the alteration in neuropsychological status, like decreased attention and concentration, memory loss, diminished psychomotor speed and decreased executive function, and this ranged from approximately 25-80% of all patients with chronic HF. [38] [39] [40] [41] Cardiologist vs internist care of patients with HF with prior stroke Cardiologists when compared with internists may provide more evidence-based therapies for the treatment of patients with HF. 42 43 This is supported by this study, where patients under the care of cardiologists had a lower risk of recurrent in-hospital stroke, major bleeding, the need for blood transfusion and lower in-hospital and 1-year mortality rates when compared with patients managed by internists. This suggests that patients with prior stroke are a higher risk group which may benefit from specialised care. On the other hand, the observational nature of this study does not adjust for the possibility of selection bias in that patients with "lower" risk stroke were "preferentially" admitted under the care of cardiologists rather than internists.
STUDY LIMITATIONS
This study is a subanalysis of an observational study, which is like any observational study, where the possibility for unmeasured confounding variables exists. In addition, not all hospitals in each country participated; hence, the results cannot be generalised. This study did not record the cognitive status and the disability status in patients with stroke, which obviously have a major impact on morbidity and mortality and only 1-year mortality. Mortality rates at follow-up were only recorded at 1 year without the specification of the exact date of death of each patient, and hence the Kaplan-Meier curves could not have been done. Finally, no information was available regarding the cause of stroke (embolic vs thrombotic). Future studies need to overcome these limitations.
CONCLUSION
This observational study reports a high prevalence of prior stroke in Middle Eastern patients with HF. There was underuse of anticoagulation therapy in patients with stroke and HF with AF. Patients with stroke hospitalised with HF were more likely to be admitted under the care of internists rather than cardiologists, resulting in less use of evidencebased medications and worse outcome. Patients with stroke had a higher risk of in-hospital recurrent strokes and higher long-term mortality rates. History of stroke was an independent predictor of in-hospital and 1-year mortality rates in patients hospitalised with HF. Future studies are needed to evaluate whether aggressive evidence based therapies to this high-risk group will improve outcome. Table 8 Prevalence of stroke in patients with HF/studies from different parts of the world Gulf CARE, Gulf aCute heArt failuRe rEgistry.
